QC
NGEN

Quadrature Capital’s NervGen Pharma NGEN Stock Holding History

Quadrature Capital’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277K Buy
+134,518
New +$417K ﹤0.01% 1233

Other funds holding NGEN

PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
AC
AXQ Capital Jersey City, New Jersey $920M AUM 18.71% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
AIP
Almanack Investment Partners Wayne, Pennsylvania $785M AUM 34.37% 1-Year Est. Return
SI
Sprott Inc Toronto, Ontario, Canada $3.15B AUM 70.1% 1-Year Est. Return

Quadrature Capital's NGEN Position: Q2 2026 in Review

Quadrature Capital opened a new position in NervGen Pharma (NGEN) in Q2 2026: 134,518 shares worth $277K. The stake represents ﹤0.01% of the portfolio and ranks #1233 among its holdings.

21 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • Quadrature Capital held 134,518 shares of NervGen Pharma worth $277K as of Q2 2026.
  • NervGen Pharma was a new Quadrature Capital position in Q2 2026.
  • NervGen Pharma made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1233 holding.
  • 21 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.